Twist Bioscience Corporation (TWST) has a negative trailing P/E of -39.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 116.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -2.54%, forward earnings yield 0.86%. PEG 0.77 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -6.0 | 0.00 | -3.43 | 115.88 | - |
| 2017 | -4.4 | -0.13 | -1.97 | 24.42 | - |
| 2018 | -5.2 | 0.34 | -1.85 | 14.65 | - |
| 2019 | -6.1 | -0.13 | 4.31 | 12.06 | - |
| 2020 | -21.3 | 2.38 | 8.85 | 33.04 | - |
| 2021 | -33.9 | 2.88 | 8.89 | 39.00 | - |
| 2022 | -8.7 | -0.31 | 2.41 | 9.33 | - |
| 2023 | -5.6 | 0.52 | 1.85 | 4.70 | - |
| 2024 | -12.6 | 0.00 | 5.55 | 8.38 | - |
| 2025 | -21.7 | 0.34 | 3.56 | 4.47 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.35 | $2.27M | $-44.09M | -1943.1% |
| 2017 | $-3.16 | $10.77M | $-59.31M | -550.8% |
| 2018 | $-2.68 | $25.43M | $-71.24M | -280.2% |
| 2019 | $-3.92 | $54.39M | $-107.67M | -198% |
| 2020 | $-3.57 | $90.1M | $-139.93M | -155.3% |
| 2021 | $-3.15 | $132.33M | $-152.1M | -114.9% |
| 2022 | $-4.04 | $203.57M | $-217.86M | -107% |
| 2023 | $-3.60 | $245.11M | $-204.62M | -83.5% |
| 2024 | $-3.60 | $312.97M | $-208.73M | -66.7% |
| 2025 | $-1.30 | $376.57M | $-77.67M | -20.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.82 | $-1.96 – $-1.67 | $438.81M | $438.19M – $439.49M | 4 |
| 2027 | $-1.20 | $-1.21 – $-1.18 | $504.92M | $496.51M – $510.12M | 4 |
| 2028 | $-0.60 | $-1.32 – $0.14 | $581.97M | $581.71M – $582.24M | 6 |
| 2029 | $0.50 | $0.49 – $0.50 | $662.55M | $655.1M – $668.6M | 3 |
| 2030 | $1.24 | $1.22 – $1.25 | $761.95M | $753.38M – $768.91M | 2 |
